NCT04370834 2025-02-04Tocilizumab for Patients With Cancer and COVID-19 DiseaseNational Cancer Institute (NCI)Phase 2 Terminated1 enrolled 10 charts
NCT00421174 2021-11-01BMTCTN0403National Heart, Lung, and Blood Institute (NHLBI)Phase 3 Completed37 enrolled 20 charts